IAN Angel Fund Leads Investment In Life Sciences Startup Expanding Human-Relevant Drug Testing Solutions
Bengaluru-based life sciences startup Biodimension has raised Rs 8 crore in a funding round led by IAN Angel Fund. The round also saw participation from existing investor Campus Angels Network, Dr. Sampath Srisailam, and angel investor Aaryan Baid.
The fresh capital will be used to accelerate product development, expand laboratory infrastructure, strengthen scientific and commercial teams, and support the commercialization of its products across India and international markets.
The funding comes as pharmaceutical, biotechnology, and cosmetic companies increasingly seek alternatives to animal testing amid evolving regulations and growing demand for more accurate human-relevant research models.
What Does Biodimension Do?
Founded by Manojkumar S., Ranjith Kumar Velusamy, and Pradeep Arunachalam, Biodimension develops biofabricated human tissue and organoid models that can be used for drug discovery, toxicity testing, disease research, and safety assessments.
The company’s solutions are designed to provide more reliable human-based testing environments while reducing dependence on traditional animal testing methods.
Its product portfolio includes BioDEpi, BioDFT, BioDPigma, a Pan-Cancer Tumour Microenvironment (TME) Biobank, and Bioassay-as-a-Service (BaaS), which support pharmaceutical research and precision medicine applications.
Funding To Support Expansion And Commercialization
According to the company, the newly raised funds will help scale research and development efforts while expanding laboratory capabilities.
Biodimension also plans to strengthen its scientific workforce and commercial operations as it prepares for broader market expansion.
The startup intends to accelerate the commercialization of its products across India while expanding its presence in overseas markets.
Growing Focus On Oncology And Drug Discovery
Biodimension said it has already established collaborations with pharmaceutical companies, biotechnology firms, research institutions, and contract research organizations (CROs) across India and Singapore.
The company now plans to deepen its focus on oncology research by expanding its cancer-focused testing platforms and Pan-Cancer Tumour Microenvironment Biobank.
It also aims to scale its Bioassay-as-a-Service platform, enabling researchers and enterprises to access advanced biological testing infrastructure without building in-house capabilities.
Human Tissue Models Gain Momentum Globally
The global life sciences industry is witnessing a shift toward human-relevant testing models as regulators and researchers seek alternatives that can deliver more accurate insights into human biology.
Organoids, biofabricated tissues, and advanced cell-based models are increasingly being used for drug screening, toxicity testing, and personalized medicine applications.
With rising demand for next-generation biomedical research tools, Biodimension is positioning itself as a key player in the emerging biofabrication and organoid technology ecosystem.
The company also plans to expand into additional international markets, including Southeast Asia, as it scales its commercial footprint.
